Re: AGM - Jan 7, 2016 - Details
in response to
by
posted on
Jan 13, 2016 10:23AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Toniv,
I wasn't aware of this either. But a quick google search turned up this Annual Information Form from 2006 for Resverlogix and on page 8 it describes the Apsley/Resverlogix reverse takeover that occured in April 2003.
BearDownAZ